Igenomix Acquires Access Genomics Canada from Persistence Capital Partners

Dotmatics Acquires SoftGenetics to Expand Genetic Analysis Capabilities

June 12, 2023

Software

Dotmatics has acquired SoftGenetics, a bioinformatics software company that provides genetic analysis tools for research, clinical, and forensic applications. The acquisition expands Dotmatics' R&D scientific software portfolio by adding SoftGenetics' suite of sequencing and genotyping products while allowing SoftGenetics to operate as a standalone business within Dotmatics.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.

Twist Bioscience Acquires iGenomX

June 30, 2021

Biotechnology

Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15, 2019

Healthcare Services

Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.

EQT Acquires Igenomix from Charme Capital; Management and Charme Reinvest

June 18, 2019

Biotechnology

EQT VIII (EQT Partners) has agreed to acquire a majority stake in Igenomix, a Valencia-headquartered leader in reproductive genetic services, from Charme Capital, management and other minority owners. Charme Capital and the Igenomix management team will reinvest significant minority stakes, and EQT will support the company's continued international expansion and R&D-led growth.

Affymetrix Acquires Panomics for Approximately $73M

November 11, 2008

Biotechnology

Affymetrix Inc. agreed to acquire Panomics Inc., a Fremont, California–based provider of low- to mid-plex genetic and protein assay products, for approximately $73 million in cash. The purchase is intended to expand Affymetrix's product portfolio and enable a more complete genetic-analysis workflow—linking whole-genome microarray studies with targeted Panomics assays—and is expected to close by the end of 2008 subject to customary conditions.